FDA Requires Vision Loss Warnings on GLP-1 Diabetes and Weight-Loss Drugs
The US Food and Drug Administration (FDA) has mandated new warning labels on GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, due to a rare risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden, painless vision loss. The FDA's analysis found a slightly higher incidence of this eye condition among users compared to placebos. Both companies are reviewing the data, with Novo maintaining confidence in their drugs' benefit-risk profiles. Patients experiencing vision issues are advised to seek medical attention promptly.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 55/100.
Outlets measured: businessstandard, economictimes, economictimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (45–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 9 Nov, 05:46 pm. Other outlets followed.